Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the launch of an innovative Fourier 80 multinuclear benchtop FT-NMR spectrometer, known as the ‘Multi-Talent’ configuration.
Cognito Therapeutics, a pioneering neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, announced new data from its OVERTURE feasibility trial at the AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases.
GoodRx the leading platform for medication savings in the U.S., announced a new e-commerce experience for retail pharmacies that improves how consumers get their medications via the GoodRx platform. The company is launching the experience with Midwest-based retailer Hy-Vee.
Sierra Space, a leading commercial space company and defense tech prime that is Building a Platform in Space to Benefit Life on Earth,® and Yuri, a Germany-based space biotech company, announced an agreement for one new ScienceTaxi BioSpin mission to continue biological and medical research advancements and drug discovery in microgravity. The culmination of the partnership will ultimately aim to provide scientific solutions for treating and curing diseases on Earth.
Pint Pharma and PharmaEssentia announced that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® (ropeginterferon alfa-2b) for the treatment of adult patients with Polycythemia Vera (PV).
Orthofix Medical Inc. a leading global medical technology company, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and the European CE Mark for the TrueLok™ Elevate Transverse Bone Transport (TBT) System.
PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies.
Kincell Bio, a leader in cell therapy development and manufacturing, is excited to announce the appointment of Larry Pitcher as Chief Operating Officer (COO). Larry brings extensive experience in the advanced therapies Contract Development and Manufacturing Organization (CDMO) space, having had P&L responsibility, deep operational experience including facility expansions and key leadership roles.
Shed, a telehealth clinic specializing in weight loss, is excited to announce Low-Dose Naltrexone (LDN), an innovative, therapeutic solution for individuals managing chronic pain, autoimmune diseases, and metabolic health challenges. LDN works by naturally balancing the immune system, reducing inflammation, and providing pain relief, offering a much-needed alternative for patients seeking to address the root causes of their conditions.
QOL Medical, LLC, a ground-breaking rare disease pharmaceutical company, has announced Sucraid® (sacrosidase) Oral Solution has been shown to be 81% effective in treating patients with Congenital Sucrase-Isomaltase Deficiency (CSID) when used appropriately.1 Eligible patients can now try Sucraid® for free with a 4-day trial offer through their medical provider.